ImmunityBio
IBRX
193 hedge funds and large institutions have $391M invested in ImmunityBio in 2024 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 63 increasing their positions, 46 reducing their positions, and 21 closing their positions.
143% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 21
37% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 46
17% more funds holding
Funds holding: 165 → 193 (+28)
10% more capital invested
Capital invested by funds: $357M → $391M (+$34.1M)
0.91% less ownership
Funds ownership: 9.85% → 8.95% (-0.91%)
31% less call options, than puts
Call options by funds: $24.8M | Put options by funds: $35.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$9.28M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$9.2M |
| 3 |
BlackRock
New York
|
+$6.91M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$5.85M |
| 5 |
AWM
Accurate Wealth Management
Wesley Chapel,
Florida
|
+$3.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$41.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$7.95M |
| 3 |
Citigroup
New York
|
-$6.72M |
| 4 |
Rafferty Asset Management
New York
|
-$5.77M |
| 5 |
PA
Perceptive Advisors
New York
|
-$5.65M |
IBRX Hedge Fund Activity: Q2 2024 in Review
193 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q2 2024, worth a combined $391M — up 9.6% from $357M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new IBRX positions and 21 closed out — a net gain of 30 holders — while 63 added to existing stakes and 46 trimmed.
The largest buyer was Jane Street, adding an estimated $9.28M. The largest seller was State Street, cutting an estimated $41.7M.
- 193 institutional investors held ImmunityBio (IBRX) as of Q2 2024, up from 165 in Q1 2024.
- Funds reported $391M of ImmunityBio stock for Q2 2024, up 9.6% quarter-over-quarter.
- 51 funds opened new ImmunityBio positions in Q2 2024 and 21 closed out, a net change of +30 holders.
- The largest ImmunityBio buyer in Q2 2024 was Jane Street, an estimated $9.28M added.
- The largest ImmunityBio seller in Q2 2024 was State Street, an estimated $41.7M sold.
Based on aggregated 13F filings for Q2 2024.